Investment Rating - The investment rating for the company is "Buy" [7][5]. Core Insights - The company reported a strong growth in net profit for Q3 2025, reaching RMB 126.87 billion, a year-on-year increase of 92%, aligning with previous forecasts [1]. - The annualized total investment return for the first three quarters was 6.42%, up by 1.04 percentage points year-on-year, driven by strong equity investment performance [3]. - The new business value (NBV) for life insurance increased by 41.8% year-on-year, with a significant acceleration from the 20.3% growth in the first half of 2025, indicating robust sales performance [2]. - The company’s new single premium income grew by 52% year-on-year in Q3 2025, contributing to the overall profit increase [2]. - The net asset value at the end of Q3 2025 rose by 19% compared to the end of Q2 2025, reflecting strong profit growth [1]. Summary by Sections Financial Performance - The company achieved a total investment income of RMB 368.55 billion in the first three quarters, a 41% increase year-on-year, primarily due to strong equity investments [3]. - The insurance service performance saw a significant increase of 229% in Q3 2025, influenced by interest rate fluctuations [4]. - The estimated EPS for 2025 is adjusted to RMB 6.08, with target prices maintained at RMB 52 for A-shares and HKD 29 for H-shares [5]. Business Growth - The sales force at the end of Q3 2025 comprised 607,000 agents, a 3% increase from the previous quarter, indicating stable growth despite a 5% year-on-year decline [2]. - The proportion of floating products in the first-year premium income increased by over 45 percentage points, reflecting a shift in product structure [2]. Valuation - The valuation is based on a DCF method, with target prices reflecting an average of intrinsic value and book value methods [12].
中国人寿(601628):NBV强劲增长